SCHEMBL10055010

SCHEMBL10055010

Oc1ccc(NCc2ccc(CNc3ccc(O)cc3)cc2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.80
MEN1 O00255 5/20 0.80
KMT2A Q03164 5/20 0.80
GAA P10253 5/20 0.80
BLM P54132 4/20 0.80
ALDH1A1 P00352 4/20 0.80
L3MBTL1 Q9Y468 4/20 0.80
KDM4E B2RXH2 3/20 0.80
THRB P10828 3/20 0.80
POLB P06746 2/20 0.80
HPGD P15428 2/20 0.80
ALOX15 P16050 2/20 0.80
MAPK1 P28482 2/20 0.80
CASP1 P29466 2/20 0.80
HSD17B10 Q99714 2/20 0.80
ALOX12 P18054 2/20 0.80
AGER Q15109 1/20 0.80
HSP90AA1 P07900 1/20 0.80
HSP90AB1 P08238 1/20 0.80
PLEC Q15149 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795311 1.00 MAPT (0.80) MAPTMEN1KMT2AGAABLM
SCHEMBL22773430 0.93 MAPT (0.71) MAPTMEN1KMT2AGAABLM
SCHEMBL13057543 0.89 MAPT (1.00) MAPTMEN1KMT2AGAABLM
SCHEMBL18598523 0.89 MAPT (0.67) MAPTMEN1KMT2AGAABLM
SCHEMBL2475709 0.89 MAPT (0.67) MAPTMEN1KMT2AGAABLM
SCHEMBL6555950 0.89 MAPT (1.00) MAPTMEN1KMT2AGAABLM
SCHEMBL6557993 0.89 MAPT (0.67) MAPTMEN1KMT2AGAABLM
SCHEMBL14950714 0.89 MAPT (1.00) MAPTMEN1KMT2AGAABLM
SCHEMBL14680444 0.89 AGER (1.00) MAPTMEN1KMT2AGAABLM
SCHEMBL6556042 0.89 MAPT (0.67) MAPTMEN1KMT2AGAABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779583-B2 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction EMORY UNIVERSITY (US) 2023-10-10 US disclosed
US-11779583-B2 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction EMORY UNIVERSITY (US) 2023-10-10 US disclosed
US-20210401836-A1 TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION EMORY UNIVERSITY (US) 2021-12-30 US disclosed
US-10632120-B2 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction EMORY UNIVERSITY (US) 2020-04-28 US disclosed
US-20180104243-A1 Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction EMORY UNIVERSITY 2018-04-19 US disclosed
US-20180104243-A1 Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction EMORY UNIVERSITY 2018-04-19 US disclosed
EP-2776387-B1 TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION UNIV EMORY (US) 2017-02-01 EP disclosed
US-20160058761-A1 Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction METASTATIX, INC. 2016-03-03 US disclosed
US-20160058761-A1 Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction METASTATIX, INC. 2016-03-03 US disclosed
US-20160002174-A1 CXCR4 Antagonists for the Treatment of Medical Disorders EMORY UNIVERSITY 2016-01-07 US disclosed
US-8080659-B2 CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders EMORY UNIVERSITY (US) 2011-12-20 US disclosed
US-8008312-B2 CXCR4 antagonists for the treatment of HIV infection EMORY UNIVERSITY (US) 2011-08-30 US disclosed
US-8008312-B2 CXCR4 antagonists for the treatment of HIV infection EMORY UNIVERSITY (US) 2011-08-30 US disclosed
WO-2008008854-A9 CXCR4 ANTAGONISTS INCLUDING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS UNIV EMORY (US) 2008-03-27 WO disclosed
WO-2008008854-A2 CXCR4 ANTAGONISTS INCLUDING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS EMORY UNIVERSITY (US) 2008-01-17 WO disclosed
US-20070054930-A1 CXCR4 antagonists for the treatment of medical disorders EMORY UNIVERSITY 2007-03-08 US disclosed
US-20070054930-A1 CXCR4 antagonists for the treatment of medical disorders EMORY UNIVERSITY 2007-03-08 US disclosed
US-4258129-A IMPROVE GREEN SHELF LIFE FUJI PHOTO FILM CO., LTD. (JP) 1981-03-24 US disclosed
US-4211839-A SILVER HALIDE AND ORGANIC SILVER SALT PREPARED IN AN IMINO COMPOUND FUJI PHOTO FILM CO., LTD. (JP) 1980-07-08 US disclosed
US-4188212-A BEZNOTRIAZOLE FUJI PHOTO FILM CO., LTD. (JP) 1980-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210401836-A1 TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION SHBG, ABAT, GLS MAPT 3864/4885MEN1 500/4885KMT2A 2632/4885
US-10632120-B2 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction SHBG, ABAT, GLS MAPT 3864/4885MEN1 500/4885KMT2A 2632/4885
US-20070054930-A1 CXCR4 antagonists for the treatment of medical disorders CXCR4, CXCL12, CXCR1 MAPT 4435/4885MEN1 2244/4885KMT2A 3853/4885
US-20160058761-A1 Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction SHBG, ABAT, GLS MAPT 3864/4885MEN1 500/4885KMT2A 2632/4885
US-11779583-B2 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction SHBG, ABAT, GLS MAPT 3864/4885MEN1 500/4885KMT2A 2632/4885
US-20160002174-A1 CXCR4 Antagonists for the Treatment of Medical Disorders CXCR4, CXCL12, CXCR1 MAPT 4435/4885MEN1 2244/4885KMT2A 3853/4885
US-20180104243-A1 Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction SHBG, ABAT, GLS MAPT 3864/4885MEN1 500/4885KMT2A 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.